Cerity Partners
LSTA icon

Cerity Partners’s Lisata Therapeutics LSTA Stock Holding History

Cerity Partners’s Portfolio LSTA Stock Details LSTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$41.4K Hold
12,183
– – ﹤0.01% 3313
2026
Q1 		$61K Hold
12,183
– – ﹤0.01% 3086
2025
Q4 		$49.1K Hold
12,183
– – ﹤0.01% 2806
2025
Q3 		$30.7K Hold
12,183
– – ﹤0.01% 2714
2025
Q2 		$32.3K Buy
+12,183
New +$29.3K ﹤0.01% 2583

Other funds holding LSTA

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
YCM
Yakira Capital Management Westport, Connecticut $351M AUM 21.8% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.57B AUM 67.14% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
GS
GTS Securities New York $4.75B AUM 41.97% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Cerity Partners's LSTA Position: Q2 2026 in Review

Cerity Partners held its Lisata Therapeutics (LSTA) position steady in Q2 2026 at 12,183 shares worth $41.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3313.

Cerity Partners first reported a position in LSTA in Q2 2025 and has held it in 5 quarters since. The position peaked at $61K in Q1 2026. 27 funds tracked by Wall St. Rank hold LSTA as of Q2 2026.

  • Cerity Partners held 12,183 shares of Lisata Therapeutics worth $41.4K as of Q2 2026.
  • Cerity Partners left its Lisata Therapeutics share count unchanged in Q2 2026.
  • Lisata Therapeutics made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #3313 holding.
  • Cerity Partners first reported a position in Lisata Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Cerity Partners's Lisata Therapeutics position peaked at $61K in Q1 2026.
  • 27 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.